ClinicalTrials.gg
Active, not recruitingNCT07716618Updated Jul 21, 2026

A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

A Phase 2 interventional study of SAL0120 1mg and SAL0120 2mg in Chronic Kidney Disease, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 246 studies in Renal Insufficiency, Chronic with a site in China — 95 open to participants now, 108 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
57th of 165
320 · median 182
Started
2025
with 27 others
Phase 2
22 of 246
5 open now
Primary completion
2026-05
later than 30 of 107 live
Registered
237th of 246
by date

Among the 246 studies in Renal Insufficiency, Chronic with a site in China, this one is the 57th largest by planned enrollment of the 165 interventional ones that give a count, is one of 28 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 30 of the 107 other live ones, and was the 237th registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

95 of the 246 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

90 more — sign in →

All 95 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 246 (57%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial designed to investigate the efficacy and safety of different doses of sal0120 tablets in patients with CKD.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. On the day of signing the , the age is 18-75 years old (including the boundary value), regardless of gender;
  2. at a stable dose within 12 weeks before screening;
  3. During screening, the patient is diagnosed with chronic kidney disease, and the estimated eGFR calculated based on the CKD-EPI formula (see Appendix 1 for details) is ≥20 mL/min/1.73 m2;
  4. At screening visit 1, the urine albumin/creatinine ratio (UACR) measured twice on different days within ≤7 days must meet ≥300 and \<5000 mg/g at the same time;
  5. (BMI) ≤40 kg/m2;
  6. All male subjects and female subjects of agree to use highly effective methods for contraception from the date of signing the ICF until 1 month after the last dose of the drug (see Appendix 2 for details).
  7. Be able to understand the procedures and methods of this study, and be willing to strictly abide by the clinical trial protocol and complete this trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients suspected or diagnosed with polycystic kidney disease (autosomal dominant and recessive), rapidly progressive glomerulonephritis; patients with acute kidney injury or receiving peritoneal dialysis or hemodialysis treatment within 6 months before the screening period;
  2. Known history of heart failure or disease related to fluid overload (such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites).
  3. Cardiovascular diseases that are not suitable for participation in the study: ① Primary heart valve disease, severe mitral/tricuspid regurgitation; patients planning to undergo heart valve repair or replacement; ② Patients with stroke, myocardial infarction, cerebral infarction (except asymptomatic cerebral infarction), and within 6 months before screening; ③ Carotid artery surgery or carotid artery angioplasty within 3 months before screening. ④Acute coronary syndrome (ACS)-related events within 3 months before screening; ⑤Congenital syndrome, history of other drug-related QT interval prolongation, prolongation of QT interval on at screening visit 1 or at randomization (visit 2) (male QTcF>470 ms; female QTcF>480 ms); ⑥ The electrocardiogram results at screening visit 1 show abnormalities, such as supraventricular tachycardia, atrial fibrillation, atrial flutter, second or third degree atrioventricular block, etc.;
  4. Have used systemic glucocorticoids or within 3 months before screening, excluding topical or intra-articular, intranasal and inhaled glucocorticoids; have used rituximab and cytotoxic drugs within 6 months before screening;
  5. Have received strong inhibitors or inducers of P-gp within 2 weeks before screening (for example: ranolazine, verapamil, itraconazole, clarithromycin, quinidine, ritonavir, tipranavir, saquinavir, etc.); have received strong inhibitors or inducers of within 2 weeks before screening (for example: rifampicin, phenytoin, carbamazepine, ketoconazole, etc.);
  6. Concomitant with the following clinically significant, unstable or uncontrolled diseases within 6 months before screening, including but not limited to respiratory system, digestive system, cardiovascular and cerebrovascular, endocrine, immune, urinary, adrenal, blood, neurological, psychiatric and other diseases or other medical diseases that may confuse the research results and bring additional risks to the subjects.
  7. Acute complications of diabetes such as diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma, lactic acidosis, and hypoglycemic coma occurred within 6 months before the screening period; and there were complications requiring acute treatment at screening visit 1, including but not limited to: proliferative vitreoretinopathy, maculopathy, painful diabetic peripheral neuropathy, and diabetic foot (ulcer, infection);
  8. Patients with poorly controlled hypertension (for example, screening visit 1 and random blood pressure show systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), or systolic blood pressure \<90mmHg;
  9. Nt-proBNP ≥ 600pg/mL at screening visit 1;
  10. (HbA1c) ≥9% at screening visit 1;
  11. Patients with type 1 diabetes;
  12. \<90g/L at screening visit 1, or a history of blood transfusion to treat anemia within 3 months of screening.
  13. Have a history of pulmonary hypertension (WHO group 1), idiopathic pulmonary fibrosis or any lung disease requiring oxygen therapy (for example: , emphysema, pulmonary edema, etc.);
  14. Patients with a history of organ transplantation (except patients with a history of corneal transplantation) or patients who plan to have a kidney transplant during the study period;
  15. Known or suspected allergy to the study drug or its components or ;
  16. Patients with malignant tumors (including hematological ), except for the following circumstances: tumors determined to be cured or in remission for 5 years, basal cell or squamous cell carcinoma of the skin that has been radically removed, or carcinoma in situ at any location;
  17. Patients with severe hepatobiliary system diseases (for example, or ALT >2 times the value at Screening Visit 1, or patients with liver cirrhosis, or total >2 times the upper limit of normal value at Screening Visit 1);
  18. Have a history of alcohol or drug abuse within 1 year before screening. Alcohol abuse is defined as: drinking more than 14 units of alcohol per week (1 unit of alcohol = 360ml of beer or 45ml of spirits with an alcohol content of 40% or 150ml of wine);
  19. People with serious mental illness, including but not limited to: schizophrenia, bipolar disorder, depression, mania, etc.;
  20. Patients with active (if hepatitis B surface antigen is positive, HBV DNA testing is required. If hepatitis B surface antigen is positive and the HBV DNA test is >500 copies/mL or >100 IU/mL, patients with active hepatitis B must be excluded). (if the HCV antibody test is positive, HCV RNA testing is required. If the HCV antibody test is positive and the HCV RNA result is positive, hepatitis C patients must be excluded); patients with active syphilis (if the Treponema pallidum antibody test is positive, antibody titer testing is required, and patients with active syphilis are excluded according to the center's testing standards); -positive patients, whose condition is in a stable stage, can be included by the researcher based on the comprehensive performance of the subjects;
  21. Patients who are pregnant, lactating, or have the possibility of pregnancy (based on the pregnancy test results of screening visit 1, the researcher cannot rule out the possibility of pregnancy);
  22. Patients who have been treated with other experimental drugs (or drugs) or treated with experimental medical devices (or research devices) within 3 months before screening and before randomization, or who are participating in interventional clinical research (a medical behavior that exceeds routine diagnosis and treatment, performed for research purposes) and receiving treatment;
  23. Any other medical condition that, in the opinion of the investigator, may pose a safety risk to the subjects in this study, may confound the evaluation of efficacy or safety, or may interfere with the subject's participation in the study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    SAL0120 1mg

    Drug: SAL0120 1mg

  • Experimental
    SAL0120 2mg

    Drug: SAL0120 2mg

  • Experimental
    SAL0120 4mg

    Drug: SAL0120 4mg

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • DrugSAL0120 1mg

    SAL0120 1mg

  • DrugSAL0120 2mg

    SAL0120 2mg

  • DrugSAL0120 4mg

    SAL0120 4mg

  • DrugPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. The baseline relative change in UACR;The change from baseline in UACR across SAL0120 dose groups

    At 12 weeks of treatment, the changes in UACR (urinary albumin/creatinine ratio) relative to baseline were compared in each group; the differences in the changes in UACR relative to baseline among different dose groups of SAL0120 tablets were assessed.

    Time frame: at 12 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2026, 16 months.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 138 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartActual
Jan 17, 2025
Primary completionActual
May 27, 2026
CompletionEst.
Aug 31, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07716618
Collaborators
Salubris (Suzhou) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Jan 17, 2025
Primary completion
May 27, 2026
Completion
Aug 31, 2026 (estimated)
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion